Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
12 hedge funds and large institutions have $265K invested in Genetic Technologies Ltd. in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
276% more call options, than puts
Call options by funds: $417K | Put options by funds: $111K
8% less funds holding
Funds holding: 13 → 12 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
36% less capital invested
Capital invested by funds: $413K → $265K (-$148K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$48.6K |
| 2 |
VF
Virtu Financial
New York
|
+$20K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.5K |
| 4 |
PFS
Prospera Financial Services
Dallas,
Texas
|
+$972 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$748 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$63.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$46.8K |
| 3 |
Millennium Management
New York
|
-$41K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$21.8K |
| 5 |
HWAM
Hennion & Walsh Asset Management
Parsippany,
New Jersey
|
-$21K |
GENE Hedge Fund Activity: Q1 2022 in Review
12 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q1 2022, worth a combined $265K — down 36% from $413K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GENE and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was Credit Suisse, opening a new position worth an estimated $48.6K. The largest seller was Morgan Stanley, cutting an estimated $63.1K.
- 12 institutional investors held Genetic Technologies Ltd. (GENE) as of Q1 2022, down from 13 in Q4 2021.
- Funds reported $265K of Genetic Technologies Ltd. stock for Q1 2022, down 36% quarter-over-quarter.
- 3 funds opened new Genetic Technologies Ltd. positions in Q1 2022 and 4 closed out, a net change of -1 holder.
- The largest Genetic Technologies Ltd. buyer in Q1 2022 was Credit Suisse, an estimated $48.6K added.
- The largest Genetic Technologies Ltd. seller in Q1 2022 was Morgan Stanley, an estimated $63.1K sold.
Based on aggregated 13F filings for Q1 2022.